The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Semiserin V.A.

Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia

Karakozov A.G.

Evdokimov Moscow State Medical Dentistry University, Moscow, Russia

Malkuta M.A.

Consulting and Diagnostic Polyclinic, City Clinical Hospital Fifty-Nine, Moscow Healthcare Department, Moscow, Russia

Zolotareva L.A.

Consulting and Diagnostic Polyclinic, City Clinical Hospital Fifty-Nine, Moscow Healthcare Department, Moscow, Russia

Levchenko O.B.

Evdokimov Moscow State Medical Dentistry University, Moscow, Russia

Kalyagin I.E.

Evdokimov Moscow State Medical Dentistry University, Moscow, Russia

Eremin M.N.

Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia

Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis

Authors:

Semiserin V.A., Karakozov A.G., Malkuta M.A., Zolotareva L.A., Levchenko O.B., Kalyagin I.E., Eremin M.N.

More about the authors

Journal: Therapeutic Archive. 2016;88(2): 58‑63

DOI: 10.17116/terarkh201688258-63

Views: 1948

Downloaded: 591

Download PDF (RU)
Contact the author
Table of contents

EVALUATION OF THE EFFICIENCY OF HEPATOPROTECTIVE MONOTHERAPY USING SUCCINIC ACID AND METHIONINE FOR NONALCOHOLIC FATTY LIVER DISEASE AT THE STAGE OF STEATOHEPATITIS
EVALUATION OF THE EFFICIENCY OF HEPATOPROTECTIVE MONOTHERAPY USING SUCCINIC ACID AND METHIONINE FOR NONALCOHOLIC FATTY LIVER DISEASE AT THE STAGE OF STEATOHEPATITIS

To cite this article:

Semiserin VA, Karakozov AG, Malkuta MA, Zolotareva LA, Levchenko OB, Kalyagin IE, Eremin MN. Evaluation of the efficiency of hepatoprotective monotherapy using succinic acid and methionine for nonalcoholic fatty liver disease at the stage of steatohepatitis. Therapeutic Archive. 2016;88(2):58‑63. (In Russ.)
https://doi.org/10.17116/terarkh201688258-63

МСФ на ЯМ
Close metadata
Recommended articles:
Serum uric acid — a meta­bolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42
Human diseases treatment via enema fecal microbiota transplantation. Methodological reco­mmendations. Russian Journal of Preventive Medi­cine. 2024;(6):79-87
Cognitive beha­vioral therapy in the treatment of patients with chro­nic migraine and concomitant chro­nic inso­mnia: a prospective, randomized trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5-2):110-117
Late-onset schi­zophrenia and schi­zophrenia-like psychosis with very late onset. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):32-40
Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chro­nic kidney disease. Russian Journal of Preventive Medi­cine. 2024;(8):114-120
Unre­solved problem: Chemotherapy-Induced Peri­pheral Neuropathy. P.A. Herzen Journal of Onco­logy. 2024;(5):76-81
Multiparametric ultrasound effe­ctiveness in dete­cting and moni­toring non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):25-33
Liver and bone in tandem: osteopenia as an inevitable companion to non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):40-50
Hepa­tocellular carcinoma asso­ciated with nona­lcoholic fatty liver disease. P.A. Herzen Journal of Onco­logy. 2024;(6):57-62
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90

Aim. To evaluate the efficiency of Remaxol monotherapy in patients with nonalcoholic fatty liver disease (NAFLD) at the stage of steatohepatitis (SH). Subjects and methods. The treatment of 156 patients with NAFLD at the stage of SH was analyzed. A study group included 84 patients who had received intravenous Remaxol, 400 ml, dropwise at a rate of 40—60 drops per minute once daily in the morning for 10 days; a control group of 72 patients had been treated with the conventional scheme. Results. During the treatment, the study group showed a rapider relief of the manifestations of asthenovegetative and dyspeptic syndromes and a reduction in the magnitude of biochemical manifestations of cytolytic and cholestatic syndromes than did the control group. Conclusion. Incorporation of Remaxol into the therapy regimen in patients with NAFLD at the stage of SH enhances the effectiveness of treatment.

Keywords:

non-alcoholic fatty liver disease
steatohepatitis
therapy
Remaxol

Authors:

Semiserin V.A.

Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia

Karakozov A.G.

Evdokimov Moscow State Medical Dentistry University, Moscow, Russia

Malkuta M.A.

Consulting and Diagnostic Polyclinic, City Clinical Hospital Fifty-Nine, Moscow Healthcare Department, Moscow, Russia

Zolotareva L.A.

Consulting and Diagnostic Polyclinic, City Clinical Hospital Fifty-Nine, Moscow Healthcare Department, Moscow, Russia

Levchenko O.B.

Evdokimov Moscow State Medical Dentistry University, Moscow, Russia

Kalyagin I.E.

Evdokimov Moscow State Medical Dentistry University, Moscow, Russia

Eremin M.N.

Consulting and Diagnostic Polyclinic, Therapeutic and Diagnostic Center Nine, Ministry of Defense of the Russian Federation, Moscow, Russia

List of references:

  1. Bueverov A.O., Maevskaya M.V. Nekotorye patogeneticheskie i klinicheskie voprosy nealkogol'nogo steatogepatita. Klinicheskie perspektivy gastroenterologii, gepatologii. 2003;3:2-7. 
  2. Ludwig J, Viggiano TR. Non-alcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-438.
  3. Neuschwander-Tetri BA, Saldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Singl Topic Conference. Hepatology. 2003;37(5):1202-1219.
  4. Ivashkin V.T., Drapkina O.M. Shul'pekova Yu.O. Diagnostika i lechenie nealkogol'noi zhirovoi bolezni pecheni. Metodicheskie rekomendatsii. M.; 2015.
  5. Mazina N.K., Mazin P.V., Sukhanov D.S. Klinicheskaya effektivnost' suktsinatsoderzhashchego infuzionnogo preparata pri farmakoterapii porazhenii pecheni razlichnogo geneza po rezul'tatam metaanaliza. Terapevticheskii arkhiv. 2013;85(1):56-61.
  6. Stel'makh V.V., Kozlov V.K. Metabolicheskaya korrektsiya pri dislipidemii u bol'nykh s nealkogol'noi zhirovoi bolezn'yu pecheni kak novaya strategiya terapii. Terapevticheskii arkhiv. 2013;85(4):71-76.
  7. Zarivchatskii M.F., Kamenskikh E.D., Mugatarov I.N. Otsenka effektivnosti primeneniya Remaksola u bol'nykh tsirrozom pecheni. Khirurgiya. Zhurnal im. N.I. Pirogova. 2013;3: 79-82.
  8. Tang DG, La E, Kern J, Kehrer JP. Fatty acid oxidation and signaling in apoptosis. Biol Chem. 2002;383(3-4):425-442.
  9. Lakin G.F. Biometriya: Uchebnoe posobie dlya biologicheskikh spetsializirovannykh vuzov. M.; 1980.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.